Sponsor Provided Content

Fifteen years ago, the medical world was rocked by the possibilities presented by the sequencing of the complete set of genetic information for humans: the human genome. Since then, news reports almost every day include advances in the diagnosis and treatment of diseases and new insights in many fields of biology, thanks to that key achievement. It’s helped us understand how we all have genetic variants that put us at increased or decreased risk of getting various diseases.

Those variants also make us more or less responsive to specific treatment, an aspect of “precision medicine” which President Obama even touched on in his State of The Union Address in January. Using a patient’s genetic markers to help tailor drug therapies for his/her disease is the burgeoning field of pharmacogenomics. In layman’s terms, it’s a way to customize a medication treatment plan to maximize each patient’s results.

Dr. Richard Kovach is the Chair of Interventional Cardiology and the Director of the Cardiac Catheterization Laboratory at Deborah Heart and Lung Center in Burlington County, the only hospital in our area that applies pharmacogenomic testing to the treatment of cardiovascular disease.

KYW’s Rasa Kaye talks with him about personalized medicine and how pharamacogenomics can help predict a patient’s response to a cardiac drug medication.

DNA StrandDNA Strand
Courtesy of Deborah Heart & Lung


To learn more, visit Deborah.org »